252 Randomized controlled trial of PEGinterferon alfa-2A plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients

Thakeb, Fouad; Omar, Mahmoud; Awady, Mostafa M.E.I.; Isshak, Sherif Y.

doi:10.1016/s0270-9139(03)80295-1

Cited by 23 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, 56% of the patients with chronic HCVG4 showed an SVR, which is in agreement with other studies in which SVR rates of 55-60% have been reported [28,29]; in some studies, it reaches 69% [30,31]. However, studies Values are presented as mean±SD unless indicated otherwise.…”

Section: Discussionsupporting

confidence: 92%

Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4

Saad

Ahmed²,

Saleh³

et al. 2013

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4

Saad

Ahmed²,

Saleh³

et al. 2013

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

“…We could not correlate between the different subtypes and clinical picture, gender, residence, or liver biopsy results due to the low number of cases studied. In Egypt, the response of genotype 4 to interferon treatment was reported in many studies [El-Zayadi et al, 1999;Esmat et al, 2002;Thakeb et al, 2003], however there are no available data of the response of subtypes 4a and 4c to interferon treatment.…”

Section: Discussionmentioning

confidence: 99%

TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4

et al. 2005

View full text Add to dashboard Cite

Hepatitis C virus genotypes and subtypes determination is an important factor for understanding the epidemiology of the virus, in the pre-treatment evaluation of the patients and in defining better treatment strategies. In the present study, we compared two commercially available assays for HCV genotyping: the reverse hybridization based Innogenetics INNO-LiPA HCV II and the direct sequencing by TRUGENE assay. The study included 31 HCV-RNA positive Egyptian patients; 18 patients with chronic active hepatitis, 8 with HCC, and 5 with cirrhosis. Using the TRUGENE genotyping test, all the samples had genotype 4 (100%) and subtyped as 4a in 18/31(58%), 4c in 10/31 (32%), 4e in 1/31 (3%), 4a/c in 1/31 (3%), and 4g in 1/31 (3%). Using the INNO-LiPA assay, 30 samples had genotype 4 (97%), and 1 sample had genotype 1e (3%). One sample showed mixed infection with type 4f and type 1. Only six samples were subtypable by INNO-LiPA, three were genotype 4c/d, and the other three were 4f, 4e, and 1e. Seven samples gave reactivity in the INNO-LiPA of lines 5, 6, 16, 17, 18, which are considered untypable by the interpretation chart but considered to be a rare HCV genotype 4 by the manufacturer. At the genotype level, there was a 97% concordance between TRUGENE sequencing and INNO-LiPA, but at the subtype level the concordance rate was 3% only. We conclude that the TRUGENE genotyping assay is a reliable test for HCV genotyping for the detection of major types and subtypes detection, while INNO-LiPA is a good test at the genotype level but unreliable for subtyping especially in the Egyptian population. This is mainly due to the high diversity of genotype 4, which is the most prevalent genotype in Egypt.

show abstract

“…In patients with genotype 4 infection, higher SVR (79%) was achieved with peginterferon alfa-2a plus ribavirin 1,000 or 1,200 mg/day for 48 wk than with other regimens with shorter treatment durations (67%), lower ribavirin doses (63%), or peginterferon alfa-2a monotherapy (44%) (38,39). Similarly, high SVR was demonstrated with 36 or 48 wk of treatment with peginterferon alfa-2b and ribavirin in genotype 4-infected patients (SVR 66% and 69%, respectively) (40).…”

Section: Patients With Genotype 4-6 Infectionsmentioning

confidence: 99%

Management and Treatment of Hepatitis C Viral Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office

Yee

Currie

Darling

et al. 2006

Am J Gastroenterology

139

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection affects approximately 1.3% of the general U.S. population and 5-10% of veterans who use Department of Veterans Affairs medical services. Chronic HCV is clearly linked to the development of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease requiring liver transplantation. The consequences of HCV infection constitute a significant disease burden and demonstrate the need for effective medical care. Treatment of chronic HCV is aimed at slowing disease progression, preventing complications of cirrhosis, reducing the risk of HCC, and treating extrahepatic complications of the virus. As part of a comprehensive approach to HCV management, antiviral therapy with peginterferon alfa combined with ribavirin is the current standard of care. Antiviral therapy should be provided to those individuals who meet criteria for treatment and who are at greatest risk for progressive liver disease. Many of these patients may have comorbid medical and psychiatric conditions, which may worsen while on antiviral therapy. Current antiviral regimens are associated with significant adverse effects that can lead to noncompliance, dose reduction, and treatment discontinuation. To overcome these barriers and to address these issues, it has become crucial to facilitate a multidisciplinary team who can respond to and provide HCV-specific care and treatment. Screening for HCV, preventing transmission, delaying disease progression, ensuring appropriate antiviral therapy, and managing treatment-related adverse effects can improve patient quality of life, treatment adherence, and ultimately, improve patient outcomes.

show abstract

252 Randomized controlled trial of PEGinterferon alfa-2A plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients

Cited by 23 publications

References 0 publications

Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4

Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4

TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4

Management and Treatment of Hepatitis C Viral Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office

Contact Info

Product

Resources

About